| 1 |
Completion of Preclinical Studies and Phase 2b IND Approval of J2H-1702, a MASH Drug Candidiate |
| Small molecules |
MASH |
11β-HSD1 |
Preclinical |
J2H BIOTECH |
RS-2026-25503865 |
|
| 2 |
Development of a Novel Triple Agonist(HM15272)-Based Transdermal Drug Delivery System for Obesity Treatment |
| rProtein |
Obesity |
GLP-1, GIP and Glucagon receptor |
Preclinical |
Hanmi Pharm. Co., Ltd. |
RS-2026-25502086 |
|
| 3 |
Preclinical development of KARS1-target drug candidate with broad and high efficacy for treatment of MASH (metabolic dysfunction-associated steatohepatitis) |
| Small molecules |
MASH |
KARS1 |
Preclinical |
Zymedi |
RS-2025-02202980 |
|
| 4 |
Preclinical Development of a UniStac®.based Long.acting Tetraspecific Drug for NASH |
| rProtein |
NASH |
FGF21,GLP.1,GCG,a.cytokine |
Preclinical |
Onegene Biotechnology Inc. |
RS-2023-00282937 |
|
| 5 |
LPA1 antagonist AMS-III-1086; Pre-clinical study for liver fibrosis treatment |
| Small molecules |
Liver fibrosis |
LPAR1 |
Preclinical |
am SCIENCES |
HN22C0594 |
|
| 6 |
Pre-clinical study of YH34160 for obesity treatment |
| rProtein |
Obesity |
GDF15 |
Preclinical |
Yuhan |
HN22C0555 |
|